Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides

Journal of Medicinal Chemistry

Volumn 48, Issue 9, 2005, Pages 3344-3353

  Mai, Antonello ^a   Massa, Silvio ^b   Pezzi, Riccardo ^a   Simeoni, Silvia ^a   Rotili, Dante ^a   Nebbioso, Angela ^c   Scognamiglio, Annamaria ^c   Altucci, Lucia ^b,d   Loidl, Peter ^e   Brosch, Gerald ^e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (3 PHENYL 3 OXO 1 PROPEN 1 YL) 1 METHYL 1H PYRROL 2 YL] N HYDROXY 2 PROPENAMIDE; 3 [4 (3 PHENYL 3 OXOPROPEN 1 YL) 1 METHYL 1H PYRROL 2 YL] N HYDROXY 2 PROPENAMIDE; 3 [4 [3 (3 CHLOROPHENYL) 3 OXOPROPEN 1 YL] 1 METHYL 1H PYRROL 2 YL] N HYDROXY 2 PROPENAMIDE; 3 [4 [3 (3 FLUOROPHENYL) 3 OXOPROPEN 1 YL] 1 METHYL 1H PYRROL 2 YL] N HYDROXY 2 PROPENAMIDE; 3 [4 [3 (4 CHLOROPHENYL) 3 OXO 1 PROPEN 1 YL] 1 METHYL 1H PYRROL 2 YL] 2 PROPENOIC ACID; BENZENE; BUTYRIC ACID; FR 901228; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; NAPHTHYL GROUP; PYRROLE DERIVATIVE; TRAPOXIN; TRICHOSTATIN A; TUBACIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CHEMICAL MODIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GRANULOCYTE; HUMAN; HUMAN CELL; MAIZE;

AMIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASES; HUMANS; PROPANE; PYRROLES; REPRESSOR PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; U937 CELLS; ZEA MAYS;

EID: 20944435415     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049002a     Document Type: Article

References (87)

1. Hassig, C. A.; Schreiber, S. L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr. Opin. Chem. Biol. 1997, 1, 300-308.
2. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications. Nature 2000, 403, 41-45.
3. Wu, J.; Grunstein, M. 25 Years after the nucleosome model: chromatin modifications. Trends Biochem. Sci. 2000, 25, 619-623.
4. Wolffe, A. P.; Guschin, D. Chromatin structural features and targets that regulate transcription. J. Struct. Biol. 2000, 129, 102-122.
5. Cheung, W. L.; Briggs, S. D.; Allis, C. D. Acetylation and chromosomal functions. Curr. Opin. Cell Biol. 2000, 12, 326-333.
6. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349-352.
7. Kouzarides, T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 1999, 9, 40-48.
8. Roth, S.; Denu, J. M.; Allis, C. D. Histone acetyltransferases. Annu. Rev. Biochem. 2001, 70, 81-120.
9. Grant, P. A.; Berger, S. L. Histone acetyltransferase complexes. Semin. Cell Dev. Biol. 1999, 10, 169-177.
10. Cress, W. D.; Seto, E. Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. 2000, 184, 1-16.
11. Ng, H. H.; Bird, A. Histone deacetylases: silencers for hire. Trends Biochem. Sci. 2000, 25, 121-126.
12. Ferreira, R.; Magnaghi-Jaulin, L.; Robin, P.; Harel-Bellan, A.; Trouche, D. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10493-10498.
13. Stiegler, P.; De Luca, A.; Bagella, L.; Giordano, A. The COOH-terminal region of pRb2/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter. Cancer Res. 1998, 58, 5049-5052.
14. Nagy, L.; Kao, H.-Y.; Chakravarti, D.; Lin, R. J.; Hassig, C. A.; Ayer, D. E.; Schreiber, S. L.; Evans, R. M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997, 89, 373-380.
15. Alland, L.; Muhle, R.; Hou, H.; Potes, J.; Chin, L.; Schreiber-Agus, N.; DePinho, R. A. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 1997, 387, 49-55.
16. Heinzel, T.; Lavinsky, R. M.; Mullen, T.-M.; Soderstrom, M.; Laherty, C. D.; Torchia, J.; Yang, W.-M.; Brard, G.; Ngo, S. D.; Davie, J. R.; Seto, E.; Eisenman, R. N.; Rose, D. W.; Glass, C. K.; Rosenfeld, M. G. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptionalrepression. Nature 1997, 387, 43-48.
17. Weidle, U. H.; Grossmann, A. Inhibition of Histone Deacetylases: a New Strategy to Target Epigenetic Modifications for Anticancer Treatment. Anticancer Res. 2000, 20, 1471-1486.
18. Kramer, O. H.; Göttlicher, M. G.; Heinzel, T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 2001, 12, 294-300.
19. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 2001, 13, 477-483.
20. Marks, P. A.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1, 194-202.
21. Jung, M. Inhibitors of Histone Deacetylase as New Anticancer Agents. Curr. Med. Chem. 2001, 8, 1505-1511.
22. Vigushin, D. M.; Coombes, R. C. Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs 2002, 13, 1-13.
23. Johnstone, R. W. Histone deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discovery 2002, 1, 287-299.
24. Kelly, W. K.; O'Connor, O. A.; Marks, P. A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs 2002, 11, 1695-1713.
25. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem. 2003, 46, 5097-5116.
26. Grozinger, C. M.; Schreiber, S. L. Deacetylase Enzymes: Biological Functions and the Use of Small-Molecule Inhibitors. Chem. Biol. 2002, 9, 3-16.
27. Gao, L.; Cueto, M. A.; Asselbergs, F.; Atadja, P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 2002, 277, 25748-25755.
28. Gregoretti, I. V.; Lee, Y.-M.; Goodson, H. V. Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic Analysis. J. Mol. Biol. 2004, 338, 17-31.
29. Verdin, E.; Dequiedt, F.; Kasler, H. G. Class II histone deacetylases: versatile regulators. Trends Genet. 2003, 19, 286-293.
30. Bertos, N. R.; Wang, A. H.; Yang, X.-J. Class II histone deacetylases: Structure, function, and regulation. Biochem. Cell Biol. 2001, 79, 243-252.
31. Fischle, W.; Kiermer, V.; Dequiedt, F.; Verdin, E. The emergency role of class II histone deacetylases. Biochem. Cell Biol. 2001, 79, 337-348.
32. Verdel, A.; Khochbin, S. Identification and characterization of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers. J. Biol. Chem. 1999, 274, 2440-2445.
33. Fischle, W.; Emiliani, S.; Hendzel, M. J.; Nagase, T.; Nomura, N.; Voelter, W.; Verdin, E. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1p. J. Biol. Chem. 1999, 274, 11713-11720.
34. Grozinger, C. M.; Hassig, C. A.; Schreiber, S. L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4868-4873.
35. De Ruijter, A. J. M.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg A. B. P. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370, 737-749.
36. Zhang, C. L.; McKinsey, T. A.; Chang, S.; Antos, C. L.; Hill, J. A.; Olson, E. N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110, 479-488.
37. Dequiedt, F.; Kasler, H. G.; Fischle, W.; Kiermer, V.; Weinstein, M.; Herndier, B. G.; Verdin, E. HDAC7, a thymus-specific Class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003, 18, 687-698.
38. Fischer, D. D.; Cai, R.; Bhatia, U.; Asselbergs, F. A.; Song, C.; Terry, R.; Trogani, N.; Widmer, R.; Atadja, P.; Cohen, D. Isolation and characterization of a novel class II histone deacetylase, HDAC10. J. Biol. Chem. 2002, 277, 6656-6666.
39. Kao, H. Y.; Lee, C. H.; Komarov, A.; Han, C. C.; Evans, R. M. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem. 2002, 277, 187-193.
40. McKinsey, T. A.; Zhang, C. L.; Olson, E. N. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 2002, 27, 40-47.
41. McKinsey, T. A.; Zhang, C. L.; Olson, E. N. Control of muscle development by dueling HATs and HDACs. Curr. Opin. Genet. Dev. 2001, 11, 497-504.
42. Gruffat, H.; Manet, E.; Sergeant, A. MEF2-mediated recruitment of class II HDAC at the EBV immediate early gene BZLF1 links latency and chromatin remodeling. EMBO Rep. 2002, 3, 141-146.
43. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X. F.; Yao, T. P. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417, 455-458.
44. Matsuyama, A.; Shimazu, T.; Sumida, Y.; Saito, A.; Yoshimatsu, Y.; Seigneurin-Berny, D.; Osada, H.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Horinouchi, S.; Yoshida, M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002, 21, 6820-6831.
45. Göttlicher, M.; Minucci, S.; Zhu, P.; Krämer, O. H.; Schimpf, A.; Giavara, S.; Sleeman, J. P.; Lo Coco, F.; Nervi, C.; Pelicci, P. G.; Heinzel, T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20, 6969-6978.
46. Fumurai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.-H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases. Cancer Res. 2002, 62, 4916-4921.
47. Fumurai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 87-92.
48. Guardiola, A. R.; Yao, T.-P. Molecular Cloning and Characterization of a Novel Histone Deacetylase HDAC10. J. Biol. Chem. 2002, 277, 3350-3356.
49. Sternson, S. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Synthesis of 7200 Small Molecules Based on a Substructural Analysis of the Histone Deacetylase Inhibitors Trichostatin and Trapoxin. Org. Lett. 2001, 3, 4239-4242.
50. Wong, J. C.; Hong, R.; Schreiber, S. L. Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity. J. Am. Chem. Soc. 2003, 225, 5586-5587.
51. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Butcher, R. A.; Schreiber, S. L. Multidimensional Chemical Genetic Analysis of Diversity-Oriented Synthesis-Derived Deacetylase Inhibitors Using Cell-Based Assays. Chem. Biol. 2003, 10, 383-396.
52. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4389-4394.
53. Tong, J. K. Dissecting Histone Deacetylase Function. Chem. Biol. 2002, 9, 668-670.
54. Massa, S.; Mai, A.; Sbardella, G.; Esposito, M.; Ragno, R.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a New Class of Synthetic Histone Deacetylase Inhibitors. J. Med. Chem. 2001, 44, 2069-2072.
55. Mai, A.; Massa, S.; Ragno, R.; Esposito, M.; Sbardella, G.; Nocca, G.; Scatena, R.; Jesacher, F.; Loidl, P.; Brosch, G. Binding Mode Analysis of 3-(4-Benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamide: A New Synthetic Histone Deacetylase Inhibitor Inducing Histone Hyperacetylation, Growth Inhibition, and Terminal Cell Differentiation. J. Med. Chem. 2002, 45, 1778-1784.
56. Mai, A.; Massa, S.; Ragno, R.; Cerbara, I.; Jesacher, F.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. I. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed Through Three Different Docking Procedures. J. Med. Chem. 2003, 46, 512-524.
57. Mai, A.; Massa, S.; Cerbara, I.; Valente, S.; Ragno, R.; Bottoni, P.; Scatena, R.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy- 2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole C2 and/or C4 Substitutions on Biological Activity. J. Med. Chem. 2004, 47, 1098-1109.
58. Ragno, R.; Mai, A.; Massa, S.; Cerbara, I.; Valente, S.; Bottoni, P.; Scatena, R.; Jesacher, F.; Loidl, P.; Brosch, G. 3-(4-Aroyl-1-methyl-1H-pyrrol- 2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studies. J. Med. Chem. 2004, 47, 1351-1359.
59. Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone Deacetylation in Epigenetics: an Attractive Target for Anticancer Therapy. Med. Res. Rev. 2004, DOI 10.1002/med.20024.
60. Mai, A.; Cerbara, I.; Valente, S.; Massa, S.; Walker, L. A.; Tekwani, B. L. Antimalarial and Antileishmanial Activities of Aroyl-Pyrrolyl-Hydroxyamides, a New Class of Histone Deacetylase Inhibitors. Antimicrob. Agents Chemother. 2004, 48, 1435-1436.
61. Lusser, A.; Brosch, G.; Loidl, A.; Haas, H.; Loidl, P. Identification of maize histone deacetylase HD2 as an acidic nucleolar phosphoprotein. Science 1997, 277, 88-91.
62. Wittich, S.; Scherf, H.; Xie, C.; Brosch, G.; Loidl, P.; Gerhäuser, C.; Jung, M. Structure-Activity Relationships on Phenylalanine-Containing Inhibitors of Histone Deacetylase: In Vitro Enzyme Inhibition, Induction of Differentiation, and Inhibition of Proliferation in Friend Leukemic Cells. J. Med. Chem. 2002, 45, 3296-3309.
63. Mai, A.; Massa, S.; Pezzi, R.; Rotili, D.; Loidl, P.; Brosch, G. Discovery of (Aryloxopropenyl)pyrrolyl Hydroxamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A. J. Med. Chem. 2003, 46, 4826-4829.
64. Mai, A.; Massa, S.; Pezzi, R.; Valente, S.; Loidl, P.; Brosch, G. Synthesis and Biological Evaluation of 2-, 3-, and 4-Acylaminocinnamyl-N- hydroxyamides as Novel Synthetic HDAC Inhibitors. Med. Chem. 2005, 25, 261-309.
65. Kölle, D.; Brosch, G.; Lechner, T.; Pipal, A.; Helliger, W.; Taplick, J.; Loidl, P. Different types of maize histone deacetylases are distinguished by a highly complex substrate and site specificity. Biochemistry 1999, 38, 6769-6773.
66. Lechner, T.; Lusser, A.; Pipal, A.; Brosch, G.; Loidl, A.; Goralik-Schramel, M.; Sendra, R.; Wegener, S.; Walton, J. D.; Loidl, P. RPD3-Type histone deacetylases in maize embryos. Biochemistry 2000, 39, 1683-1692.
67. Brosch, G.; Goralik-Schramel, M.; Loidl, P. Purification of histone deacetylase HD1-A of germinating maize embryos. FEBS Lett. 1996, 393, 287-291.
68. Brosch, G.; Georgieva, E.; Lopez-Rodas, G.; Lindner, H.; Loidl, P. Specificity of zea mays histone deacetylase is regulated by phosphorylation. J. Biol. Chem. 1992, 267, 20561-20564.
69. Curtin, M.; Glaser, K. Histone Deacetylase Inhibitors: The Abbott Experience. Curr. Med. Chem. 2003, 10, 2373-2392.
70. Li, J.; Staver, M. J.; Curtin, M. L.; Holms, J. H.; Frey, R. R.; Edalji, R.; Smith, R.; Michaelides, M. R.; Davidsen, S. K.; Glaser, K. B. Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci. 2004, 74, 2693-2705.
71. Sinisterra, J. V.; Mouloungui, Z.; Delmas, M.; Gaset, A. Barium hydroxide as catalyst in organic reactions. V. Application in the Horner reaction under solid-liquid phase-transfer conditions. Synthesis 1885, 1097-1100.
72. Mori, K.; Koseki, K. Synthesis of trichostatin A, a potent differentiation inducer of Friend leukemic cells, and its antipode. Tetrahedron 1988, 44, 6013-6020.
73. 74-76
74. Lechner, T.; Lusser, A.; Brosch, G.; Eberharter, A.; Goralik-Schramel, M.; Loidl, P. A comparative study of histone deacetylases of plant, fungal and vertebrate cells. Biochim. Biophys. Acta 1998, 2296, 181-188.
75. Brosch, G.; Lusser, A.; Goralik-Schramel, M.; Loidl, P. Purification and characterization of a high molecular weight histone deacetylase complex (HD2) of maize embryos. Biochemistry 1993, 35, 15907-15914.
76. Kolle, D.; Brosch, G.; Lechner, T.; Lusser, A.; Loidl, P. Biochemical methods for analysis of histone deacetylases. Methods 1998, 15, 323-331.
77. Kruh, J. Effects of Sodium Butyrate, a New Pharmacological Agent, on Cells in Culture. Mol. Cell. Biochem. 1982, 42, 65-82.
78. Phiel, C. J.; Zhang, F.; Huang, E. Y.; Guenther, M. G.; Lazar, M. A.; Klein, P. S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 2001, 76, 36734-36741.
79. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and Specific Inhibition of Mammalian Histone Deacetylase both In Vivo and In Vitro by Trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
80. Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3003-3007.
81. Kijima, M.; Yoshida, M.; Suguta, K.; Horinouchi, S.; Beppu, T. Trapoxin, an Antitumor Cyclic Tetrapeptide, Is an Irreversible Inhibitor of Mammalian Histone Deacetylase. J. Biol. Chem. 1993, 268, 22429-22435.
82. Brosch, G.; Ransom, R.; Lechner, T.; Walton, J.; Loidl, P. Inhibition of maize histone deacetylases by HC toxin, the host-selective toxin of Cochliobolus carbonum. Plant Cell 1995, 33, 1941-1950.
83. Sambucetti, L. C.; Fischer, D. D.; Zabludoff, S.; Kwon, P. O.; Chamberlin, H.; Trogani, N.; Xu, H.; Cohen, D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 1999, 274, 34940-34947.
84. Glaser, K. B.; Li, J.; Staver, M. J.; Wei, R. Q.; Albert, D. H.; Davidsen, S. K. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 2003, 310, 529-536.
85. Mai, A.; Esposito, M.; Sbardella, G.; Massa, S. A new facile and expeditious synthesis of N-hydroxy-N′-phenyloctanediamide, a potent inducer of terminal cytodifferentiation. Org. Prep. Proced. Int. 2001, 33, 391-394.
86. Nebbioso, A.; Clarke, N.; Voltz, E.; Germain, E.; Ambrosino, C.; Bontempo, P.; Alvarez, R.; Schiavone, E. M.; Ferrara, F.; Bresciani, F.; Weisz, A.; de Lera, A. R.; Gronemeyer, H.; Altucci, L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11, 77-84.
87. Altucci, L.; Rossin, A.; Raffelsberger, W.; Reitmair, A.; Chomienne, C.; Gronemeyer, H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 2001, 7, 680-686.